Swing Trade Ideas

🏃🚀 VTAK high 3.15, up 162%

✅ TELO potential entry: $1.20

🎯 Potential PT1: $1.60 – $1.90 🎯 PT2: $2.00 – $2.50 🎯 PT3: $2.60 – $2.80

🚫 Potential Stop: Below $1.0 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
 back to near 52 weak low from recent high,  recently announced positive  preclinical data data for Telonmir-1  in breast cancer, company focuses on reversing biological aging and degenerative diseases, analyst price target $15, earnings 11/12 

✅ $STEC entry: $1.40
🎯 PT1: $1.30 – $1.80 🎯 PT2: $1.90 – $2.50 🎯 PT3: $2.60 – $3.00
🚫 Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

company focuses on consumer technology, healthcare and enterprise 

 ✅ NVVE potential entry: $0.80
🎯 PT1: $1.10–$1.70 🎯 PT2: $1.80–$2.30 🎯 PT3: $2.40–$3.50
🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently announced battery energy storage system project in Austria, company focuses on EV charging and vehicle-to-gid (V2G), recently secured $5M contract for three battery energy storage systems in Denmark, does have mixed shelf, be mindful on next spike 

 ✅ $AMC Entry: $1.05
🎯 PT1: $1.20 – $2.20
🎯 PT2: $2.30 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $0.70, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 52wk low,  Macquarie price target $2 

  ✅ FATE potential entry: $1.10–$1.15
🎯 PT1: $1.40–$1.80 🎯 PT2: $1.90–$2.50 🎯 PT3: $2.60–$3.30
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company focuses on developing cellular immunotherapies for cancer and autoimmune diseases, Wedbush buy rating, 

 ✅ BBAI entry: 3.80–3.90
🎯 PT1: 4.20–4.70 🎯 PT2: 4.80–5.50 🎯 PT3: 5.60–5.80
🚫 Stop: Below 3.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
c ompany focuses on AI software on decision intelligence for government and enterprise clients, average analyst price target $5.50 

 ✅ ONCY entry: $0.90 – $0.95
🎯 PT1: $1.20 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.80
🚫 Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company focuses on the development of first in class intravenously delivered oncolytic virus designed to selectively destroy cancer cells and stimulate the immune system against tumors, previously announced promising Pelareorep data in colorectal cancer, FDA recently agreed on phase 3 trial design for elareorep in pancreatic cancer, planning to launch immunotherapy trial in pancreatic cancer in 2026,  Lake Street buy rating,  RBC Capital buy rating, HC Wainwright raised target price to $10 from $5, director James T. Parsons recently acquired shares  

 ✅ $BKYI entry: $0.60
🎯 PT1: $0.80 – $1.40
🎯 PT2: $1.50 – $1.80
🎯 PT3: $1.90 – $2.50
🚫 Stop: Below $0.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
recently announced collaboration with TD Synnex to provide suite of security solutions to Federal, State, local government agency, partnered for identify-bound biometric with TD SYNNEXT public sector, announced strategic partnership with Visualforma, recently won contract to secure digital identifies for Major Portuguese Municipality,  collaboration news to expand its service  and Boost cybersecurity with Scandinavian IT distributor IT2Trust, recent partnership with Cloud Distribution to expand IAM and biometric security solutions across the middle east CEO and Chairman reported  recent shares purchased, company provides identify & access management and biometric authentication solutions 

 ✅ VTAK potential entry: $1.35 – $1.45
🎯 PT1: $1.60 – $2.30
🎯 PT2: $2.40 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 recently  announced merger agreement to acquire 100% of Fly Flyte,  small float, recently received new VIVO purchase order from hospital in Slovenia, Previously entered distribution agreement with FuMedica,  and announced two patents to be issued by USPTO, previously received Approval for LockeT in the United Kingdom, announced introduction of LockeT product line into Italy, company specializes in medical device based in US, two main products: VIVO system is a non-invasive, ED cardiac mapping system that integrates ECG and imaging data to help localize ventricular arrhythmia origins before procedures, the other is LockeT device, a suture retention tool designed to optimize vascular closure after percutaneous procedures, aiming to speed up hemostasis and patient recovery, 

  ✅ LRHC entry: 0.90
🎯 PT1: 1.20 – 1.80
🎯 PT2: 1.90 – 2.50
🎯 PT3: 2.60 – 3.50
🚫 Stop: Below 0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to key support near 52wk low from recent high, recently announced to acquire Consensus Core Technologies in all-stock transaction, company is a real estate brokerage and PropTech holding company, recently expanded int AI infrastructure and data centers, recent 1/10 reverse split, ultra small float, recently signed contract to acquire Central Florida Site for AI data center, 

 ✅ JCSE potential entry: $0.90 - $0.95
🎯 Potential PT1: $1.20 - $1.80
🎯 PT2: $1.90 - $2.50
🎯 PT3: $2.60 - $3.60
🚫 Potential Stop: Below $0.80 or 2%-5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high, company designs and sells industrial cleaning systems and filtration equipment used in manufacturing and food service industries, based out in Singapore 

 ✅ ORKT entry: 1.00
🎯 PT1: 1.20 - 1.60
🎯 PT2: 1.70 - 2.30
🎯 PT3: 2.40 - 2.80
🚫 Stop: Below 0.80 or 2%-5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
AI technology/software company, providing IT consultiing, enterprise software solutions, and a no-code application development platform called eMOBIQ 

 ✅ CRON potential entry: $2.40 - $2.50
🎯 Potential PT1: $2.80 - $3.40
🎯 PT2: $3.50 - $4.30
🎯 PT3: $4.40 - $5.50
🚫 Potential Stop: Below $2.20 or 2%-5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 ✅ VHUB entry: $2.05 – $2.10
🎯 PT1: $2.40 – $3.20
🎯 PT2: $3.30 – $4.30
🎯 PT3: $4.40 – $5.50
🚫 Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to near 52wk low from recent traded on NASDAQ above $40, recent offering at $2.45/share, company focuses on autonomous Smart Store technology, recently announced expanded its integration with Stripe to Power Global network of AI-driven Smart Stores, also recently secured agreements with multiple independent operators to deploy six new VenHub Smart Stores across Las Vegas, 

 ✅ WAI entry: $2.15 – $2.20

🎯 PT1: $2.50 – $2.90
🎯 PT2: $3.10 – $3.60
🎯 PT3: $3.70 – $4.20

🚫 Stop: Below $2.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 back to support from recent high, recently secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China 

 ✅ CMND entry: $1.00 – $1.05
🎯 PT1: $1.20 – $1.80
🎯 PT2: $1.90 – $2.40
🎯 PT3: $2.50 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
back to 52wk low, previopusly reported positive data for CMND - 100 in alcohol use disorder trial, recently enrolled last patient for first cohort of CMND-100 trial for the treatment of AUD (alcohol use disorder) , recently filed and announced publication of US patent application on binge drinking addiction and compulsive behaviors, also established international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD) 

  ✅ YCBD potential entry: $0.65 – $0.70
🎯 PT1: $1.30 – $2.30
🎯 PT2: $2.40 – $3.30
🎯 PT3: $3.40 – $3.80
🚫 Stop: Below $0.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently announced strategic acquisition of Bluebird Botanicals, previously announced partnership with Bevtalk distribution to expand herbal Oasis THC Selzer distribution across Florida, US based consumer wellness company focuses on CBD and hemp-derived products, have distribution channel via DTC online, $AMZN and retail partners, Maxim group buy rating 

 ✅ NXDR potential entry: $1.50 – $1.60
🎯 PT1: $1.80 – $2.60
🎯 PT2: $2.70 – $3.50
🎯 PT3: $3.60 – $3.80
🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
company provides an online forum, a neighborhood social networking platform that connects neighbors, local businesses, and public agencies including marketplace for goods and services, recently announced partnership with Waze to bring real-time traffic and road alerts to neighbors, Craigh-Hallum buy rating, hedge fund manager Erick Jackson of EMJ Capital long term price target $374, potential the next 100x runner 

 ✅ FLD potential entry: $1.30 – $1.35
🎯 PT1: $1.70 – $2.30
🎯 PT2: $2.40 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to suport, recently launched No annual fee credit card with up to 4% $BTC.X back monthly , company operates a bitcoin-financial-services platform that enables consumers to earn, save, and use $BTC.X via consumer financial products, recently partnered with Steak n' Shake for BTC.X promotion, CEO previously announced wanting BTC.X gift card to be available in holiday season, Cantor Fitzgerald price target $6.50,  Leerink partners price target $14.5, does have mixed shelf, be mindful on next spike, 

 ✅ NRSN entry: .80
🎯 PT1: 1.30 – 1.90
🎯 PT2: 2.00 – 2.70
🎯 PT3: 2.80 – 3.50
🚫 Stop: Below 0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
back to near 52wk low, recently announced positive trial results for Alzheimer's drug candidate, D. Boral Capital price target $14, Noble financial buy rating, Alliance Global Partners buy rating,  its leading drug candidate, PrimeC, a combination of ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS) has shown positive clinical data in phase 2b, currently being prepared for commercial-scale production, upcoming catalyst: 1) topline data, phase 3, 2nd of half 2026, 2) full lNDS submission later of 2026, 3) phase 2 alzheimer's trial top line expected 2026, company focuses on neurodegenerative diseases, primarily ALS, with additional pipeline programs targeting Alzheimer's and Parkinson's, does have mixed shelf, 

 ✅ SAVA potential entry: $2.10 – $2.20
🎯 Potential PT1: $2.50 – $2.70
🎯 Potential PT2: $2.80 – $2.90
🎯 Potential PT3: $3.00 – $3.70
🚫 Potential Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 CEO previously acquired shares, company focuses on developing novel treatments and diagnostics for neurogenerative diseases, especially Alzheimer's disease 

 ✅ BZAI entry: 1.05 – 1.15
🎯 PT1: 1.40 – 1.80
🎯 PT2: 1.90 – 2.50
🎯 PT3: 2.60 – 3.40
🚫 Stop: Below 1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to support, 52wk low from recent high, company develops AI edge computing chips and software platforms used for computer vision, video analytics, industrial automation and smart infrastructure, recently announced partnership with $NOK Nokia solutions and Networks Singapore, B. Riley price target $8, D.A Davidson buy rating, does have mixed shelf, be mindful on next spike, 

 ✅ XAIR potential entry: $0.80
🎯 PT1: $1.20 – $1.70
🎯 PT2: $1.80 – $2.70
🎯 PT3: $2.80 – $3.70
🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high above 2, company  is a medical device and biopharm company, focuses on therapies using nitric oxide (NO) technology, its LungFit PH is FDA-approved for pulmonary hypertension in newborns, LungFit PRO/LungFit GO - products for viral lung infections such as pneumonia, bronchiolitis) and at home treatments, NeuroNOS and oncology programs such as solid tumors with ongoing developmentrecently announced acquire 85% of Beyond Air subsidiary NeuroNOS in Autism Therapeutics,  does have mixed shelf, be mindful on next spike, D. Boral price target $11, Rodman & Renshaw buy rating 

 ✅ PRSO potential entry: $0.80
🎯 Potential PT1: $1.20 – $1.70
🎯 PT2: $1.80 – $2.50
🎯 PT3: $2.60 – $3.20
🚫 Potential Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recently filed application for orphan drug designation for NV-387 to treat measles, recently signed Master services agreements with Only Orphans Cote, company focuses on discovering and developing broad-spectrum antiviral  therapeutics,  former runner,  Alliance Global buy rating 

 ✅ XELB potential entry: $1.40–$1.50
🎯 PT1: $1.70–$2.30
🎯 PT2: $2.40–$2.80
🎯 PT3: $2.90–$3.40
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high, company focuses on medica and consumer products, designing, licensing, marketing and selling branded products, band portfolio includes Halston, Judity Ripka, C Wonder, TowerHill by Christie Brinkley, Longaberger and others across apparel, footwear, accessories, home goods, CEO Robert D'Loren and Director Mark DiSanto recently purchased shares, Noble Financial buy rating, does have mixed shelf recently filed, be mindful in next spike 

 ✅ NNVC entry: 1
🎯 PT1: 1.40–1.80
🎯 PT2: 1.90–2.50
🎯 PT3: 2.60–3.30
🚫 Stop: Below 0.85 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recently filed application for orphan drug designation for NV-387 to treat measles, recently signed Master services agreements with Only Orphans Cote, company focuses on discovering and developing broad-spectrum antiviral  therapeutics,  former runner,  Alliance Global buy rating 

 ✅ SNGX potential entry: $1.05 – $1.15

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.60
🎯 PT3: $2.70 – $3.80

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently received positive orphan drug opinion for SGX945 in Behcet's disease, upcoming catalyst:  ongoing enrollment in phase 3 trial for HyBryte, company specializing in the development and commercialization of therapies for rare and underserved diseases,  Zacks Small-cap price target $35, Alliance Global Partners price target $6, 

✅ FOFO entry: $2.90 – $2.95

🎯 PT1: $3.30 – $3.90
🎯 PT2: $4.00 – $4.60
🎯 PT3: $4.70 – $5.50

🚫 Stop: Below $2.75 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to near 52 wk low from recent IPO high above 65, a consulting and asset management firm 

  ✅ HCAT potential entry: $1.70
🎯 PT1: $2.10 – $2.80
🎯 PT2: $2.90 – $3.70
🎯 PT3: $3.80 – $4.50
🚫 Stop: Below $1.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support near 52wk low, company focuses on healthcare data analytics and technology, providing cloud based data operating system and analytic tools to hospitals and health systems, Citigroup price target $2.75, Stifel price target $3.75 

 ✅ GTBP potential entry: $0.45
🎯 PT1: $0.70 – $1.20
🎯 PT2: $1.30 – $1.80
🎯 PT3: $1.90 – $2.50
🚫 Stop: Below $0.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
recently received FDA clearance for IND, previously announced advancing phase 1 trial of GTB-3650 for relapsed blood cancers, update data expecting Q1 2026, other upcoming catalysts: 1)company develops cancer therapies using proprietary TriKE platform, designed to activate natural killer cells to attack cancer cells, ROTH MKM price target $8, does have mixed shelf, be mindful on next spike, have until May 16, 2026 to regain compliance, 

 ✅ SATL entry: $3.10 – $3.20
🎯 PT1: $3.50 – $3.90
🎯 PT2: $4.00 – $4.60
🎯 PT3: $4.70 – $5.50
🚫 Stop: Below $2.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high above 5.50, company is a satellite imaging company, providing services to military, government, defense, agriculture, oil & mining, and AI monitoring, upcoming catalysts: 1) Cantor Global Tech & Industrial Growth conference in New York on March 10-11, recently announced launching of Aleph Observer, Cantor Fitzgerald buy rating target price $7, Northland initiated outperform, recently extended existing agreement with the Government of Albania, recent offering price at $4.73 per share 

: ✅ ENLV entry: 1.05 – 1.10
🎯 PT1: 1.40 – 1.80
🎯 PT2: 1.90 – 2.60
🎯 PT3: 2.70 – 3.80
🚫 Stop: Below 0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recently closed $212M private placement, expanding digital asset strategy, adopts RAIN token treasury strategy and advances Allocetra knee osteoarthritis program, recently announced positive 6-month topline data, demonstrating durable and persistent pain reduction and improved function in primary age-rated patients with mod to severe knee osteoarthritis, company focuses on immunotherapy, main program is Allocetra, an off the shelf macrophage-reprogramming therapy intended to restore macrophages to healthy state, treating inflammatory and degenerative disease,  HC Wainwright raised price to $13 from $7 

  ✅ AUID entry: $1.25 – $1.35
🎯 PT1: $1.60 – $1.90
🎯 PT2: $2.00 – $2.40
🎯 PT3: $2.50 – $3.20
🚫 Stop: Below $1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high, company focuses on biometric identity authentication, recently selected to support retail deployments of kiosks in U.S, recently announced integration with ServiceNow to deliver secure, frictionless identity verification and authentication for contact centers 

 ✅ LRHC entry: $1.05 – $1.15
🎯 PT1: $1.40 – $1.90
🎯 PT2: $2.00 – $2.50
🎯 PT3: $2.60 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to key support near 52wk low from recent high, company is a real estate brokerage and PropTech holding company, recently expanded int AI infrastructure and data centers, recent 1/10 reverse split, ultra small float, recently signed contract to acquire Central Florida Site for AI data center, 

   ✅ CIGL potential entry: $1.55 – $1.65
🎯 Potential PT1: $2.00 – $2.50
🎯 PT2: $2.60 – $3.30
🎯 PT3: $3.40 – $3.90
🚫 Potential Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to near 52wk low from recent high, recently entered merger agreement with YOOV Group HOlding in a $600 M deal, previously acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients 

 ✅ CRDL entry: .90 – 1.00
🎯 PT1: 1.30 – 1.80
🎯 PT2: 1.90 – 2.60
🎯 PT3: 2.70 – 3.50
🚫 Stop: Below 0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
near 52wk low , recently announced positive phase II ARCHER Trial data for CardioIRx, recently secured USA patent for hear drugs, company focuses on novel anti-inflammatory and anti-fibrotic therapies for heart disease, its lead drug, CardioIRx (an oral cannabidiol formulation) is designed to treat serious cardiac conditions like acute myocarditis and recurrent pericarditis by modulating inflammatory pathways involved in fibrosis and heart damage.  First Berlin Equity Research price target $7.80, Canaccord Genuity buy rating, HC Wainwright price target $9, does have mixed shelf 

 ✅ KULR potential entry: $2.70 – $2.80
🎯 Potential PT1: $3.20 – $3.80
🎯 PT2: $3.90 – $4.50
🎯 PT3: $4.60 – $5.80
🚫 Potential Stop: Below $2.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently awarded five-year preferred battery supply agreement, previously entered join development collaboration for battery backup unit for $100M, joined Open compute project as platinum member, company develops and commercializes thermal management technologies focused on battery safety, heat dissipation and energy/system solutions 

 ✅ GNSS entry: $1.95 – $2.00
🎯 PT1: $2.30 – $2.80
🎯 PT2: $2.90 – $3.50
🎯 PT3: $3.60 – $3.90
🚫 Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently received $2M order from Singapore Navy for LRAD 950nxtS, previously announced $1M follow-on order from nuclear energy operator, also recently entered strategic partnership with Julie Parker Communications, recently received $9M order from teh US Army for its long range acoustic, also recently secured $1.7M follow-on LRAD order from southeast Asia military as part of multi-year program for long range communication device systems, company provides protective communications solutions, serving the federal, state/local government (SLED), enterprise critical infrastructure , globally in >100 countries and all 50 US states, Roth MKM buy rating 

 ✅ SNDL potential entry: $1.40 – $1.50

🎯 Potential PT1: $1.70 – $2.50
🎯 PT2: $2.60 – $3.50
🎯 PT3: $3.60 – $4.40

🚫 Potential Stop: Below $1.15 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 MJ related ticker, recently amended agreement to acquire Cannabis Retail stores,  company produces, distributes, and sells cannabis products, analyst rating price target $5 

 ✅ MVST potential entry: $2.20 – $2.30
🎯 Potential PT1: $2.60 – $3.60
🎯 PT2: $3.70 – $4.30
🎯 PT3: $4.40 – $5.00
🚫 Potential Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high above 7, recently raised 2025 gross market outlook to 35% while advancing all-solid-state battery and European partnership , company designs, develops and manufactures advanced lithium-ion battery technologies from core cell materials to full battery packs and energy-store systems, their batteries are used for electric commercial vehicles (buses, trucks, specialty vehicles), heavy duty transportation, and utility-scare energy storage systems, analysts strong buy rating, target price $6, 

  ✅ UAVS entry: $0.90 – $1.00

🎯 PT1: $1.20 – $1.50
🎯 PT2: $1.60 – $2.20
🎯 PT3: $2.30 – $3.20

🚫 Stop Loss: Below $0.80 or 2%–5% (or daily max risk per trade)

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent highi, recently announced strategic procurement in Malaysia, announced expanded into Canada with eBee VISION deployment, recently delivered First eBee X manufacturing kits to Vyom drones, marking milestone toward local production in India, previously sold eBee VISION Drones to U.S Army in Germany, partnered wit Makville to bring drones to Egypt, company designs and delivers unmanned aerial system including drones, sensors, software and data analytics solutions globally for commercial, government, agricultural, energy, infrastructure, and defense applications, does have mixed shelf, be mindful on next spike 

✅ HOTH entry: $0.90 – $1.00

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.00

🚫 Stop Loss: Below $0.80 or 2%–5% (or daily max risk per trade)

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 previously accepted into $NVDA Connect Program to accelerate AI-driven drug development, previously partnered and expanded its AI Initiative through $NVDA AI enterprise subscription license, previously entered joint venture with $SILO Pharma to commercialize VA-invented obesity Drug, expanded phase II clinical trial for HT-001, topical gel treating skin toxicities, across Europe in collaboration with ICON, recent data demonstrated significant reduction in tumor growth, announced patent to develop anti-obesity treatments with US Depart. Of Veterans Affairs, also previously purchased up to $1M of $BTC.X as treasury reverse asset, upcoming catalysts: 1) IND filing for HT-KIT, which recently announced positive data, suppressing tumor growth in preclinical models, expected to submit early 2026, Austria D. Boral capital price target $5, HC Wainwright price target $4 

✅ CGTX potential entry: $1.05

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.70
🎯 PT3: $2.80 – $3.50

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high above 2.50, clinical stage biopharmaceutical company focuses on age-related neurodegenerative diseases specifically Alzheimer's and dementia with Lew bodies, lead candidate is zervimesine (CT1812), oral formulation designed to penetrate the blood-brain barrier and target pathways implicated in neurodegeneration,  HC Wainwright price target $3,  B. Riley Securities raised price target to $3, does have mixed shelf, be mindful on next spike 

 ✅ XPON entry: $0.70 – $0.80

🎯 PT1: $1.20 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.50

🚫 Stop: Below $0.60 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

 back to support from recent high above 1, company designs, assembles, manufactures, and sells lithium iron phosphate batteries and related accessories in North America, recently announced upcoming release of three lithium battery models, announced batter models available in second half of 2026, company have until 7/28/2026 to bring price above $1 in order to regain nasdaq compliance, does have an additional 180-day extension, does have mixed shelf, be mindful on next spike, 

✅ $MRKR Potential Entry: $1.40 – $1.50
🎯 Potential PT1: $1.80 – $2.50
🎯 PT2: $2.60 – $2.70
🎯 PT3: $2.80 – $3.40

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: Medium | Catalyst-Driven | Technical Setup

back to support from recent high,recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell  therapies for hematological malignancies and solid tumors,  HC Wainwright price target  $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8, Brookline buy rating,

✅ $IKT Entry: $1.50 – $1.60
🎯 PT1: $1.90 – $2.40
🎯 PT2: $2.50 – $2.80
🎯 PT3: $2.90 – $3.40

🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 company focuses on developing therapies for neurodegenerative disorders, especially Parkinson's disease and related conditions, upcoming catalyst: phase 3 study for Pulmonary arterial hypertension expected to begin Q1 2026, HC Wainwright price target $8, Cantor Fitzgeral price target $4,  does have active mixed shelf, be mindful on next spike 

 ✅ $BMEA Entry: $1.10 – $1.20
🎯 PT1: $1.50 – $2.80
🎯 PT2: $2.90 – $3.60
🎯 PT3: $3.70 – $4.50

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high, company focuses on oral small molecule therapies for metabolic disease, such as type to diabetes and obesity, lead candidate icovamenib, targets a key protein involved in gene regulation, aiming to improve glycemic control and metabolic outcomes, upcoming catalyst: 1) Q1 2026 to enroll first participant in COVALENT -211 phase IIb trial and provide business update, Director and Officer Rainer Erdtmann recently acquired shares, Interim CEO & director recently bought 667% more shares, Rodman & Renshaw buy rating, D. Boral Capital price target $12.00, HC Wainwright buy rating 

 ✅ $AMC Entry: $1.05
🎯 PT1: $1.20 – $2.20
🎯 PT2: $2.30 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $0.70, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 52wk low,  Macquarie price target $2